Please Wait.....
Report
RNAi Technologies and Global Markets
Market Research Report I 2024-06-25 I 118 Pages I BCC Research
Description
Report Scope
The scope of this study encompasses an investigation of the ribonucleic acid interference (RNAi) technology market. BCC Research analyzes RNAi technology based on technology type: tools and reagents, diagnostics, therapeutics, and agriculture. BCC Research determines the current market status in each segment, examines its impact on future needs, and presents growth forecasts over the next six years. The report provides a detailed analysis of the market's drivers, restraints, challenges, and opportunities. It includes company profiles of key players, with detailed information about their business segments, financials, product portfolios, and recent developments. The report also provides detailed information on emerging technologies and new developments in the market; examines the regulatory landscape; provides a patent and pipeline analysis; and discusses ESG developments, the investment outlook, and deals within the market.
Report Includes
- 26 data tables and 53 additional tables
- An overview of the global market for RNAi technologies
- Analysis of global market trends, featuring revenue data for 2021- 2023, estimated figures for 2024, forecasts for 2029, and projected CAGRs through 2029
- Evaluation of the current market's size and revenue growth prospects, along with a market share analysis by type, therapeutic area, delivery method, and region
- A look at innovations, technological advances, and recent product launches in the RNAi market
- Analysis of the industry's regulatory framework and policies
- A discussion of ESG challenges and ESG practices in the RNAi technologies industry
- An analysis of the key companies' market shares, proprietary technologies, and strategic alliances
- Company profiles of major players within the industry, including Alnylam Pharmaceuticals Inc., Novartis AG, Thermo Fisher Scientific Inc., and Revvity Inc.
Executive Summary
Summary:
The global market for RNAi technology is estimated to increase from $2.1 billion in 2023 to reach $4.8 billion by 2029, at a compound annual growth rate (CAGR) of 14.8% from 2024 through 2029.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Background: Genetic Material
RNA Interference Overview
RNA Interference: Mechanism of Action
Initiation Phase
Effector Phase
Small Interfering RNAs (siRNAs)
MicroRNAs (miRNAs)
Small Hairpin RNAs (shRNAs)
Chapter 3 Market Dynamics
Global Market Dynamics
Market Drivers
Increasing Prevalence of Chronic Disease
Increasing Approval of RNAi Products
Advancements in RNAi Delivery Systems
Increasing Strategic Initiatives
Convenient Dosing
Market Restraints
High Treatment Costs
Lack of Awareness
Market Opportunities
Expansion of Disease Targets
Combination Therapies
Untapped Genetic Targets
Chapter 4 Emerging Technologies and Developments
Therapeutics
Diagnostics
Circulating miRNA Diagnostics for Non-invasive Health Monitoring
Agriculture
Chapter 5 Pipeline Analysis
Chapter 6 Patent Analysis
Patent Analysis
Chapter 7 Market Segmentation Analysis
Segmentation Breakdown
Overview
Market Analysis by Technology
Therapeutics
RNAi Therapeutics Market, by Region
RNAi Therapeutics Market, by Therapeutic Area
RNAi Therapeutics Market, by Delivery Method
Diagnostics
Reagents and Tools
Agriculture
Geographic Breakdown
Market Analysis by Region
North America
Europe
Emerging Markets
Chapter 8 Competitive Intelligence
Strategic Initiatives
Competitive Analysis
Chapter 9 Sustainability in RNAi Technology Market: An ESG Perspective
Introduction to ESG
Sustainability in RNAi Technology Industry: An ESG Perspective
Environmental Initiatives
Social Initiatives
Governance Initiatives
Case Study
Concluding Remarks from BCC
Chapter 10 Appendix
Methodology
Acronyms
Sources
Company Profiles
ALNYLAM PHARMACEUTICALS INC.
ARROWHEAD PHARMACEUTICALS INC.
ARBUTUS BIOPHARMA CORP.
BAYER AG
MERCK KGAA
NOVARTIS AG
NOVO NORDISK A/S
OLIX PHARMACEUTICALS INC.
QIAGEN
REVVITY INC.
SILENCE THERAPEUTICS
SIRNAOMICS
SYLENTIS S.A.
SWITCH THERAPEUTICS
THERMO FISHER SCIENTIFIC INC.
List of Tables
Summary Table : Global Market for RNAi Technology, by Technology Type, Through 2029
Table 1 : Projected Number of Adults 50 Years and Older with ?1 Chronic Condition in the U.S., 2020-2050
Table 2 : Cost Comparison of siRNA-approved Drugs and Alternative Therapies
Table 3 : List of Selected Pipeline Molecules
Table 4 : Selected Patents for RNAi Technology, Published in 2021
Table 5 : Selected Patents for RNAi Technology, Published in 2022
Table 6 : Selected Patents for RNAi Technology, Published in 2023
Table 7 : Selected Patents for RNAi Technology, Published January to April 2024
Table 8 : Global Market for RNAi Technology, by Technology Type, Through 2029
Table 9 : RNAi Approved Drugs List
Table 10 : Global Market for RNAi Therapeutics, by Region, Through 2029
Table 11 : Global Market for RNAi Therapeutics, by Therapeutic Area, Through 2029
Table 12 : Global Market for RNAi Therapeutics, by Delivery Method, Through 2029
Table 13 : miRNA-based Diagnostic Tools Available in Clinical Settings
Table 14 : Global Market for RNAi Diagnostics, by Region, Through 2029
Table 15 : Global Market for RNAi Reagents and Tools, by Type, Through 2029
Table 16 : Global Market for RNAi Reagents and Tools, by Region, Through 2029
Table 17 : Global Market for RNAi Research Tools and Constructs, by Region, Through 2029
Table 18 : Global Market for RNAi Reagents, by Region, Through 2029
Table 19 : Global Market for RNAi Agriculture, by Region, Through 2029
Table 20 : Global Market for RNAi Technology, by Region, Through 2029
Table 21 : Strategic Initiatives in Global RNAi Technology Market, 2020-2024
Table 22 : Global Rankings of Top RNAi Reagents and Tools Manufacturers, 2022
Table 23 : Key Focus Areas in ESG Metrices
Table 24 : Environmental Initiatives, by Various RNAi Technology Companies
Table 25 : ESG Rankings for Companies in the RNAi Technology Market, 2023
Table 26 : Alnylam's ESG initiatives
Table 27 : Glossary of Terms Used in This Report
Table 28 : Report Information Sources
Table 29 : Alnylam Pharmaceuticals Inc.: Company Snapshot
Table 30 : Alnylam Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 31 : Alnylam Pharmaceuticals Inc.: Product Portfolio
Table 32 : Alnylam Pharmaceuticals Inc.: News/Key Developments, 2023
Table 33 : Arrowhead Pharmaceuticals Inc.: Company Snapshot
Table 34 : Arrowhead Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 35 : Arrowhead Pharmaceuticals Inc.: News/Key Developments, 2021-2024
Table 36 : Arbutus BioPharma Corp.: Company Snapshot
Table 37 : Arbutus Biopharma Corp.: Financial Performance, FY 2022 and 2023
Table 38 : Arbutus BioPharma Corp.: News/Key Developments, 2021-2023
Table 39 : Bayer AG: Company Snapshot
Table 40 : Bayer AG: Financial Performance, FY 2022 and 2023
Table 41 : Bayer AG: Product Portfolio
Table 42 : Bayer AG: News/Key Developments, 2023
Table 43 : Merck KGaA: Company Snapshot
Table 44 : Merck KGaA: Financial Performance, FY 2022 and 2023
Table 45 : Merck KGaA.: Product Portfolio
Table 46 : Merck KGaA: News/Key Developments, 2021-2024
Table 47 : Novartis AG: Company Snapshot
Table 48 : Novartis AG: Financial Performance, FY 2022 and 2023
Table 49 : Novartis AG: Product Portfolio
Table 50 : Novartis AG: News/Key Developments, 2020-2024
Table 51 : Novo Nordisk A/S: Company Snapshot
Table 52 : Novo Nordisk A/S: Financial Performance, FY 2022 and 2023
Table 53 : Novo Nordisk A/S: Product Portfolio
Table 54 : Novo Nordisk A/S: News/Key Developments, 2021-2023
Table 55 : OliX Pharmaceuticals Inc.: Company Snapshot
Table 56 : OliX Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023
Table 57 : OliX Pharmaceuticals Inc.: News/Key Developments, 2019-2023
Table 58 : Qiagen: Company Snapshot
Table 59 : Qiagen: Financial Performance, FY 2022 and 2023
Table 60 : Qiagen: Product Portfolio
Table 61 : Qiagen: News/Key Developments, 2023
Table 62 : Revvity Inc.: Company Snapshot
Table 63 : Revvity Inc.: Financial Performance, FY 2022 and 2023
Table 64 : Revvity Inc.: Product Portfolio
Table 65 : Revvity Inc.: News/Key Developments, 2023 and 2024
Table 66 : Silence Therapeutics: Company Snapshot
Table 67 : Silence Therapeutics: Financial Performance, FY 2022 and 2023
Table 68 : Silence Therapeutics: News/Key Developments, 2022 and 2023
Table 69 : Sirnaomics: Company Snapshot
Table 70 : Sirnaomics: Financial Performance, FY 2022 and 2023
Table 71 : Sirnaomics: News/Key Developments, 2023
Table 72 : Sylentis S.A.: Company Snapshot
Table 73 : Sylentis S.A.: News/Key Developments, 2023
Table 74 : Switch Therapeutics: Company Snapshot
Table 75 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 76 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
Table 77 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 78 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021-2023
List of Figures
Summary Figure : Global Market for RNAi Technology, by Technology Type, 2021-2029
Figure 1 : RNAi Pathway
Figure 2 : Market Dynamics of RNAi Technology
Figure 3 : Tissues Targeted by RNAi Therapeutics
Figure 4 : Patents Documented Over Time, 2010-April 2024
Figure 5 : Global Market for RNAi Technology, by Technology Type, 2021-2029
Figure 6 : Global Market Shares of RNAi Technology, by Technology Type, 2023
Figure 7 : RNAi Therapeutics Timeline, 1998-2023
Figure 8 : Global Market for RNAi Therapeutics, by Region, 2021-2029
Figure 9 : Global Market for RNAi Therapeutics, by Therapeutic Area, 2021-2029
Figure 10 : Global Market for RNAi Therapeutics, by Delivery Method, 2021-2029
Figure 11 : MicroRNA (miRNA) Biomarkers in Various Cancers
Figure 12 : Global Market for RNAi Diagnostics, by Region, 2021-2029
Figure 13 : Global Market for RNAi Reagents and Tools, by Type, 2021-2029
Figure 14 : Global Market for RNAi Reagents and Tools, by Region, 2021-2029
Figure 15 : Global Market for RNAi Research Tools and Constructs, by Region, 2021-2029
Figure 16 : Global Market for RNAi Reagents, by Region, 2021-2029
Figure 17 : Global Market for RNAi Agriculture, by Region, 2021-2029
Figure 18 : Global Market for RNAi Technology, by Region, 2021-2029
Figure 19 : Global Market Shares of RNAi Technology, by Region, 2023
Figure 20 : Global Market Shares of RNAi Technology, by Suppliers/Manufacturers, 2023
Figure 21 : Research Communities' Key Sustainable Practices in Research Laboratories
Figure 22 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023
Figure 23 : Alnylam Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023
Figure 24 : Bayer AG: Revenue Share, by Business Unit, FY 2023
Figure 25 : Bayer AG: Revenue Share, by Country/Region, FY 2023
Figure 26 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
Figure 27 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
Figure 28 : Novartis AG: Revenue Share, by Business Unit, FY 2023
Figure 29 : Novartis AG: Revenue Share, by Country/Region, FY 2023
Figure 30 : Novo Nordisk A/S: Revenue Share, by Business Unit, FY 2023
Figure 31 : Novo Nordisk A/S: Revenue Share, by Country/Region, FY 2023
Figure 32 : Qiagen: Revenue Share, by Business Unit, FY 2023
Figure 33 : Qiagen: Revenue Share, by Country/Region, FY 2023
Figure 34 : Revvity Inc.: Revenue Share, by Business Unit, FY 2023
Figure 35 : Revvity Inc.: Revenue Share, by Country/Region, FY 2023
Figure 36 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
Figure 37 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security